Resources

The ORS and zinc: A policy and advocacy primer outlines the current global status of ORS and zinc uptake and key actions to increase their scale-up, as well as advocate and communicate about improving access and use.PATH, with funding from the United States Agency for International Development and the Bill and Melinda Gates Foundation, reviewed literature and existing data sources and carried out 37 key informant interviews with global- and country-level stakeholders from five countries: Burkina Faso, Ethiopia, Kenya, Nigeria, and Pakistan.The findings summarized in this primer include key actions to scaling ORS and zinc, strategies for successful implementation, and priority areas for investment to advance progress.

This slide provides a snapshot of the respiratory syncytial virus (RSV) vaccine and monoclonal antibody (mAb) technology landscape, in the effort to track the development of RSV vaccine and mAb candidates and provide a summary of the various vaccine approaches being worked on around the world.This snapshot pairs with the RSV and mAb Trial Tracker, which provides publicly available information on clinical trials of RSV candidate vaccines and mAbs intended for prevention.

This spreadsheet provides publicly available information on clinical trials of respiratory syncytial virus (RSV) candidate vaccines and monoclonal antibodies intended for prevention.Sources of information for these trials are clinicaltrials.gov; who.int/clinical-trials-registry-platform; clinicaltrialsregister.eu; and anzctr.org.au, which includes clinical trial registries from 17 countries.Some information is also obtained through contact with investigators, sponsors, and funders of vaccine trials. This spreadsheet pairs with the RSV Vaccine and mAb Snapshot, which provides a summary of the RSV vaccine and mAb candidates in development worldwide.

This slide deck, presented at the Developing Countries Vaccine Manufacturers Network International annual general meeting in October 2024, describes updated results from a study to assess the current and planned state of vaccine manufacturing in Africa and provides insights into what’s needed to develop a robust and sustainable vaccine manufacturing ecosystem.We surveyed African vaccine manufacturers to better understand their current manufacturing capacity and capabilities, the progress they’ve made since 2023, and their future outlooks. This information can help stakeholders and funders better coordinate and prioritize actions to build a successful African vaccine manufacturing ecosystem.

On 14 October, 2024, PATH co-hosted a forum to begin the conversation on financing the remaining gaps in access to medical oxygen. The event highlighted the critical role of sustained financing and donor commitments, following the launch of the oxygen investment case commissioned by the Global Oxygen Alliance (GO2AL) and the Lancet Global Health Commission Report on Oxygen Access—and ahead of upcoming funding rounds from international donors.